BRCA1 and breast carcinoma: Olaparib was the first poly(ADP-ribose) polymerase (PARP) inhibitor to be approved for the treatment of advanced breast cancers with BRCA1/2-inherited mutations and represents the first targeted-therapy approved for TNBC2.